Today: 13 March 2026
UK Stock Market Today: FTSE 100 rises after retail sales shock as Burberry jumps
20 February 2026
2 mins read

UK Stock Market Today: FTSE 100 rises after retail sales shock as Burberry jumps

London, Feb 20, 2026, 10:22 GMT — Regular session

Main takeaways

  • The FTSE 100 trades roughly 0.5% higher late this morning, with mid-caps posting gains as well.
  • January retail sales came in stronger than expected, fueling speculation about possible Bank of England rate cuts.
  • Anglo American slipped to a $3.7 billion loss, hit once more by a fresh writedown at De Beers.

London’s blue-chip shares climbed Friday, lifted by upbeat UK economic data that kept hopes for rate cuts alive. Retailers and miners drew traders’ attention. The FTSE 100 advanced 0.5% to 10,682.01. FTSE 250? Also up 0.5%, landing at 23,700.78. The Guardian

This comes just a day after the blue-chip index pulled back from its record levels—Rio Tinto shares slid following earnings, while Centrica tumbled on a profit warning and the halt of its buyback. Reuters

Friday’s batch of survey numbers nudged the mood higher. The S&P Global UK Composite PMI, which gauges company activity, ticked up to 53.9 in February from January’s 53.7—marking the strongest reading since April 2024. A score above 50 means expansion. “The early PMI data for February bring further signs of an encouraging start to the year for the UK economy,” S&P Global chief business economist Chris Williamson said. Reuters

Retail sales pulled their weight earlier, with January volumes climbing 1.8% from December—well past the 0.2% pace economists in a Reuters poll had penciled in. Year-on-year, sales jumped 4.5%, the best since February 2022, according to official figures. “The huge 2% m/m increase in retail sales volumes excluding fuel in January suggests that consumers are opening their wallets again as budget uncertainty recedes,” said Thomas Pugh, chief economist at RSM UK. Reuters

Burberry jumped to the top of the FTSE 100 in the opening minutes, while BP and Shell slipped with crude prices pulling back. Shore Capital’s David Hughes called the retail figures “an encouraging start to 2026,” but warned of potential “big surprises” lurking in the government’s Spring Statement. London South East

Anglo American shares rose after the miner posted results showing a $2.3 billion pre-tax writedown at De Beers, cutting the diamond division’s book value to $2.3 billion and leaving Anglo with a $3.7 billion loss. CEO Duncan Wanblad said, “There is at the moment a plentiful supply of rough diamonds in the market,” and noted that the De Beers sale process is well underway. Reuters

Rio Tinto stayed in focus, with the miner posting a drop in 2025 profit—even as revenue rose and the full-year dividend held steady. The drag: operating and finance costs climbed. London South East

The market’s grip looks shaky. Oil surged Thursday as traders braced for possible U.S. strikes on Iran. The dollar also edged higher. That combination can quickly reignite inflation jitters and pressure commodity-sensitive stocks if investors pull back. The Guardian

UK assets now head into a fiscal test. After January delivered a record budget surplus, investors have zeroed in on Chancellor Rachel Reeves’ Spring Statement, set for March 3. They’re scanning for any tweak to the government’s tax-and-spend approach—anything that might sway growth forecasts or shift the outlook for interest rates. ft.com

Stock Market Today

  • ImmunityBio's Anktiva Drives Revenue Surge and Sets Focus for 2026
    March 13, 2026, 3:13 PM EDT. ImmunityBio (IBRX) reported a sharp revenue increase to $113.3 million in 2025, led by sales of Anktiva, its immunotherapy approved for specific bladder cancer. This product, approved by the FDA in April 2024, is the company's primary revenue engine, with 2025 marking its first full year of commercial momentum. Anktiva, designed to stimulate immune cells to attack cancer, is gaining traction in the U.S. with growing adoption and repeat prescribing, key signs of market acceptance. Management noted a 20% quarterly sales growth in Q4 2025. International approvals and label expansion efforts are underway, making 2026 crucial for regulatory milestones and execution. ImmunityBio's future growth relies heavily on Anktiva's success as other revenue streams remain minimal, underscoring a concentrated business model.
BAT share price ticks up in London after buyback update and “lower-end” 2026 guidance
Previous Story

BAT share price ticks up in London after buyback update and “lower-end” 2026 guidance

Sensex, Nifty 50 snap back after Thursday slide as oil and U.S. inflation data loom
Next Story

Sensex, Nifty 50 snap back after Thursday slide as oil and U.S. inflation data loom

Go toTop